Prognostic value of 18F-FDG PET/CT SUVmax before R-CHOP treatment for diffuse large B cell lymphoma: an analysis of 76 cases
- Journal of Third Military Medical University Vol. 42, Issue 17, Pages: 1693-1698(2020)
- 作者机构：
- 作者简介：
- 基金信息：
DOI：10.16016/j.1000-5404.202004326
CLC：Received：30 April 2020，
Published：15 September 2020
- 稿件说明：
移动端阅览
Chengming LEI, Lidan WANG, Wenbo LI, et al. Prognostic value of 18F-FDG PET/CT SUVmax before R-CHOP treatment for diffuse large B cell lymphoma: an analysis of 76 cases[J]. Journal of Third Military Medical University, 2020, 42(17): 1693-1698.
Chengming LEI, Lidan WANG, Wenbo LI, et al. Prognostic value of 18F-FDG PET/CT SUVmax before R-CHOP treatment for diffuse large B cell lymphoma: an analysis of 76 cases[J]. Journal of Third Military Medical University, 2020, 42(17): 1693-1698. DOI： 10.16016/j.1000-5404.202004326.
摘要
Abstract
Objective
2
To investigate the survival predictive value of the maximum standard uptake value (SUVmax) of
18
F-fluorodeoxy glucose (
18
F-FDG) in positron emission tomography/computed tomography (PET/CT) in diffuse large B cell lymphoma (DLBCL) patients before R-CHOP treatment.
Methods
2
The clinical data of 76 DLBCL patients who underwent PET/CT examination before R-CHOP treatment in our hospital from 2015 to 2019 were collected. The age
gender
18
F-FDG SUVmax value of PET/CT imaging
immunological markers and immune types of these DLBCL were analyzed using R-Studio software for prognosis by univariate and multivariate analyses. According to the
18
F-FDG SUVmax value
the 76 patients were divided into the SUVmax≤10 group and the SUVmax
>
10 group.
Chi
-square test was used to compare the differences in the age
gender
clinical stage
B symptoms
LDH level
and international prognostic index (IPI) between the 2 groups.
Results
2
Both the univariate or multivariate analyses showed that age
18
F-FDG SUVmax and IPI score were all prognostic factors for prognosis in DLBCL patients
The relative risk (
RR
) was 12.56 for those
>
60 years old/≤60 years old (95%
CI
: 3.32~47.54)
3.11 for SUVmax
>
10/SUVmax ≤10 (95%
CI
: 1.04~9.34)
and 5.67 for IPI score
>
2/≤2 (95%
CI
: 1.09~29.60). No statistical relationship were found in the expression of immunological markers
CD10
BCL-6 and MUM-1 with the prognosis (
P
>
0.05). There were no significant differences in age
clinical stage and other clinical indicators between the SUVmax≤10 group and the SUVmax
>
10 group (
P
>
0.05).
Conclusion
2
The SUVmax value of
18
F-FDG PET/CT imaging before treatment is of cert
ain significance in the survival prediction for DLBCL patients after R-CHOP chemotherapy.
关键词
Keywords
references
VAIDYA R WITZIG T E Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era Ann Oncol 2014 25 11 2124 2133 10.1093/annonc/mdu109 VAIDYA R, WITZIG T E. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era[J]. Ann Oncol, 2014, 25(11): 2124-2133. DOI:10.1093/annonc/mdu109.
李 晓倩 张 利玲 中期 18 F-FDG-PET/CT在弥漫大B细胞淋巴瘤中的疗效评价方法及临床价值 临床血液学杂志 2018 31 11 886 891 10.13201/j.issn.1004-2806.2018.11.019 李晓倩, 张利玲. 中期 18 F-FDG-PET/CT在弥漫大B细胞淋巴瘤中的疗效评价方法及临床价值[J ] . 临床血液学杂志, 2018, 31(11): 886-891. DOI:10.13201/j.issn.1004-2806.2018.11.019.
LI X Q ZHANG L L 18 F-fluorodeoxyglucose positron emission tomography for interim response assessment of diffuse large B-cell lymphoma J Clin Hematol 2018 31 11 886 891 10.13201/j.issn.1004-2806.2018.11.019 LI X Q, ZHANG L L. 18 F-fluorodeoxyglucose positron emission tomography for interim response assessment of diffuse large B-cell lymphoma[J ] . J Clin Hematol, 2018, 31(11): 886-891. DOI:10.13201/j.issn.1004-2806.2018.11.019.
PARK S MOON S H PARK L C The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma Am J Hematol 2012 87 9 937 940 10.1002/ajh.23267 PARK S, MOON S H, PARK L C, et al . The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma[J ] . Am J Hematol, 2012, 87(9): 937-940. DOI:10.1002/ajh.23267.
江 茂情 . 化疗中期 18 F-FDG PET/CT、国际预后指数(IPI)、分子表型及治疗方案在弥漫大B细胞淋巴瘤患者预后评估中的应用研究 [D ] . 广州 : 南方医科大学 , 2018 . 江茂情. 化疗中期 18 F-FDG PET/CT、国际预后指数(IPI)、分子表型及治疗方案在弥漫大B细胞淋巴瘤患者预后评估中的应用研究[D ] . 广州: 南方医科大学, 2018.
JIANG M Q . Mid-term chemotherapy 18 F-FDG PET/CT, International Prognostic Index (IPI), molecular phenotype and therapeutic regimen in patients with diffuse large B-cell lymphoma [D ] . Guangzhou : Southern Medical University , 2018 . JIANG M Q. Mid-term chemotherapy 18 F-FDG PET/CT, International Prognostic Index (IPI), molecular phenotype and therapeutic r egimen in patients with diffuse large B-cell lymphoma[D ] . Guangzhou: Southern Medical University, 2018.
LI X Q SUN X LI J Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma Cancer Med 2019 8 11 5012 5022 10.1002/cam4.2404. LI X Q, SUN X, LI J, et al . Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma[J ] . Cancer Med, 2019, 8(11): 5012-5022. DOI:10.1002/cam4.2404.
CHESON B D FISHER R I BARRINGTON S F Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification J Clin Oncol 2019 8 11 5012 5022 10.1002/cam4.2404 LI X Q, SUN X, LI J, et al . Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffus e large B-cell lymphoma[J ] . Cancer Med, 2019, 8(11): 5012-5022. DOI:10.1002/cam4.2404.
FRIDRIK M A JAEGER U PETZER A Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma Eur J Cancer 2016 58 112 121 10.1200/JCO.2013.54.8800 CHESON B D, FISHER R I, BARRINGTON S F, et al . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J ] . J Clin Oncol, 2014, 32(27): 3059-3068. DOI:10.1200/JCO.2013.54.8800.
徐 妍 徐 钢 弥漫性大B细胞淋巴瘤的临床病理研究进展 实用医院临床杂志 2014 11 3 196 200 徐妍, 徐钢. 弥漫性大B细胞淋巴瘤的临床病理研究进展[J]. 实用医院临床杂志, 2014, 11(3): 196-200, 201.DOI:10.1016/j.ejca.2016.02.004
XU Y XU G A clinicopathologic progress of diffuse large B cell lymphoma Pract J Clin Med 2014 11 3 196 200, 201. XU Y, XU G. A clinicopathologic progress of diffuse large B cell lymphoma[J]. Pract J Clin Med, 2014, 11(3): 196-200, 201.
PHANG K C HUSSIN N H ABDUL RAHMAN F Characterisation of immunogenotypes of diffuse large B-cell lymphoma Malays J Pathol 2019 41 2 101 124 PHANG K C, HUSSIN N H, ABDUL RAHMAN F, et al . Characterisation of immunogenotypes of diffuse large B-cell lymphoma[J ] . Malays J Pathol, 2019, 41(2): 101-124.
杨 刚 李 亚青 柳 喜洋 弥漫大B细胞淋巴瘤PET-CT的SUVmax与临床病理参数及预后相关性分析 肿瘤基础与临床 2018 31 2 122 125 10.3969/j.issn.1673-5412.2018.02.010. 杨刚, 李亚青, 柳喜洋, 等. 弥漫大B细胞淋巴瘤PET-CT的SUVmax与临床病理参数及预后相关性分析[J]. 肿瘤基础与临床, 2018, 31(2): 122-125. DOI:10.3969/j.issn.1673-5412.2018.02.010.
YANG G LI Y Q LIU X Y Correlation analysis between SUVmax of PET-CT and clinicalpathological factor and prognosis in the diffuse large B cell lymphoma Basic Clin Oncol 2018 31 2 122 125 10.3969/j.issn.1673-5412.2018.02.010. YANG G, LI Y Q, LIU X Y, et al . Correlation analysis between SUVmax of PET-CT and clinicalpathological factor and prognosis in the diffuse large B cell lymphoma[J ] . J Basic Clin Oncol, 2018, 31(2): 122-125. DOI:10.3969/j.issn.1673-5412.2018.02.010.
张 云 王 瑜 李 燕 18 F-FDG PET/CT在弥漫大B细胞淋巴瘤诊断和化疗中期疗效评价的研究 医学影像学杂志 2018 28 11 1858 1863 张云, 王瑜, 李燕, 等. 18 F-FDG PET/CT在弥漫大B细胞淋巴瘤诊断和化疗中期疗效评价的研究[J ] . 医学影像学杂志, 2018, 28(11): 1858-1863.
ZHANG Y WANG Y LI Y 18 F-FDG PET/CT在弥漫大B细胞淋巴瘤诊断和化疗中期疗效评价的研究 医学影像学杂志 2018 28 11 1858 1863 ZHANG Y, WANG Y, LI Y, et al . 18 F-FDG PET/CT for the diagnosis and medium-term therapeutic effect evaluation of chemotherapy in diffuse large B cell lymphoma[J ] . J Med Imaging, 2018, 28(11): 1858-1863.
TERAS L R DESANTIS C E CERHAN J R 2016 US lymphoid malignancy statistics by World Health Organization subtypes CA Cancer J Clin 2016 66 6 443 459 10.3322/caac.21357 TERAS L R, DESANTIS C E, CERHAN J R, et al . 2016 US lymphoid malignancy statistics by World Health Organization subtypes[J ] . CA Cancer J Clin, 2016, 66(6): 443-459. DOI:10.3322/caac.21357.
NGEOW J Y Y QUEK R H H NG D C E High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma Ann Oncol 2009 20 9 1543 1547 10.1093/annonc/mdp030. NGEOW J Y Y, QUEK R H H, NG D C E, et al . High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma[J ] . Ann Oncol, 2009, 20(9): 1543-1547. DOI:10.1093/annonc/mdp030.
HEDSTRM G HAGBERG O JERKEMAN M The impact of age on survival of diffuse large B-cell lymphoma—a population-based study Acta Oncol 2015 54 6 916 923 10.3109/0284186x.2014.978367 HEDSTRM G, HAGBERG O, JERKEMAN M, et al . The impact of age on survival of diffuse large B-cell lymphoma—a population-based study[J ] . Acta Oncol, 2015, 54(6): 916-923. DOI:10.3109/0284186x.2014.978367.
杜 尊国 包 芸 唐 峰 弥漫大B细胞淋巴瘤的免疫学亚型与预后的关系 复旦学报(医学版) 2009 36 3 281 287 10.3969/j.issn.1672-8467.2009.03.007 杜尊国, 包芸, 唐峰, 等. 弥漫大B细胞淋巴瘤的免疫学亚型与预后的关系[J]. 复旦学报(医学版), 2009, 36(3): 281-287. DOI:10.3969/j.issn.1672-8467.2009.03.007.
DU Z G BAO Y TANG F Immunohistochemical profiles and their prognostic role in diffuse large B-cell lymphoma J Fudan Univ Med Sci 2009 36 3 281 287 10.3969/j.issn.1672-8467.2009.03.007 DU Z G, BAO Y, TANG F, et al . Immunohistochemical profiles and their prognostic role in diffuse large B-cell lymphoma[J ] . J Fudan Univ Med Sci, 2009, 36(3): 281-287. DOI:10.3969/j.issn.1672-8467.2009.03.007.
王 烨 马 晓梅 岳 娜 原发性中枢神经系统弥漫性大B细胞淋巴瘤30例临床病理特征及生存预后分析 诊断病理学杂志 2016 23 10 736 741 10.3969/j.issn.1007-8096.2016.10.006. 王烨, 马晓梅, 岳娜, 等. 原发性中枢神经系统弥漫性大B细胞淋巴瘤30例临床病理特征及生存预后分析[J]. 诊断病理学杂志, 2016, 23(10): 736-741. DOI:10.3969/j.issn.1007-8096.2016.10.006.
WANG Y MA X M YUE N Clinicopathological characteristics and prognosis of primary diffuse large B cell lymphoma in central nervous system hin J Diagn Pathol 2016 23 10 736 741 10.3969/j.issn.1007-8096.2016.10.006. WANG Y, MA X M, YUE N, et al . Clinicopathological characteristics and prognosis of primary diffuse large B cell lymphoma in central nervous system[J ] . Chin J Diagn Pathol, 2016, 23(10): 736-741. DOI:10.3969/j.issn.1007-8096.2016.10.006.
朱 海燕 李 菲 赵 瑜 组合临床国际预后指数、病理免疫分型及中期PET/CT建立的模型在弥漫大B细胞淋巴瘤预后评估中的应用 中国医学影像学杂志 2019 27 4 298 301, 308. 10.3969/j.issn.1005-5185.2019.04.014. 朱海燕, 李菲, 赵瑜, 等. 组合临床国际预后指数、病理免疫分型及中期PET/CT建立的模型在弥漫大B细胞淋巴瘤预后评估中的应用[J]. 中国医学影像学杂志, 2019, 27(4): 298-301, 308. DOI:10.3969/j.issn.1005-5185.2019.04.014.
ZHU H Y LI F ZHAO Y Model combined with clinical international prognostic index, pathological immunophenotype and interim PET/CT in the prognosis assessment of diffuse large B-cell lymphoma Chin J Med Imaging 2019 27 4 298 301, 308. 10.3969/j.issn.1005-5185.2019.04.014. ZHU H Y, LI F, ZHAO Y, et al . Model combined with clinical international prognostic index, pathological immunophenotype and interim PET/CT in the prognosis assessment of diffuse large B-cell lymphoma[J ] . Chin J Med Imaging, 2019, 27(4): 298-301, 308. DOI:10.3969/j.issn.1005-5185.2019.04.014.
贾 存东 杨 丽丽 岳 娜 新疆维吾尔族弥漫性大B细胞淋巴瘤患者免疫学亚型及预后分析 中国老年学杂志 2014 34 7 1798 1800 10.3969/j.issn.1005-9202.2014.07.031. 贾存东, 杨丽丽, 岳娜, 等. 新疆维吾尔族弥漫性大B细胞淋巴瘤患者免疫学亚型及预后分析[J]. 中国老年学杂志, 2014, 34(7): 1798-1800. DOI:10.3969/j.issn.1005-9202.2014.07.031.
JIA C D YANG L L YUE N Immunological subtypes and prognostic analysis of diffuse large B cell lymphoma in Xinjiang Uygur people Chin J Gerontol 2014 34 7 1798 1800 10.3969/j.issn.1005-9202.2014.07.031. JIA C D, YANG L L, YUE N, et al . Immunological subtypes and prognostic analysis of diffuse large B cell lymphoma in Xinjiang Uygur people[J ] . Chin J Gerontol, 2014, 34(7): 1798-1800. DOI:10.3969/j.issn.1005-9202.2014.07.031.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
